ARTICLE
12 January 2021

Product-by-Process Anticipation Analyses Apply To Product-by-Process Limitations Nested Within Method-of-Treatment Claims

WS
Winston & Strawn LLP

Contributor

Winston & Strawn LLP is an international law firm with 15 offices located throughout North America, Asia, and Europe. More information about the firm is available at www.winston.com.
In reversing a district court's judgment as a matter of law (JMOL) of no anticipation, the Federal Circuit clarified that a method-of-treatment claim reciting a product-by-process...
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

Biogen MA Inc. v. EMD Serano, Inc., No. 19-1133 (Fed. Cir. Sept. 28, 2020)

In reversing a district court's judgment as a matter of law (JMOL) of no anticipation, the Federal Circuit clarified that a method-of-treatment claim reciting a product-by-process limitation can be anticipated by prior art disclosing the same product produced by a different process.

At the district court, the jury found anticipation of claims reciting a method of treatment with a pharmaceutically effective amount of a recombinant polypeptide.  In particular, the evidence showed that an identical amino acid sequence for the polypeptide was disclosed in the prior art, albeit in its native form, rather than in recombinant form.  Following the jury verdict, the district court granted JMOL of no anticipation, holding that no reasonable jury could find anticipation because the prior art did not disclose the recombinant form of the polypeptide.  In reaching this conclusion, the district court declined to apply a product-by-process analysis to a product-by-process limitation recited by the claims.  The district court alternatively opined that even under a product-by-process analysis, the recombinant form of the polypeptide required a three-dimensional structure, and there was insufficient evidence that the prior art disclosed such a structure.

The Federal Circuit reversed the district court's JMOL of no anticipation and remanded with instructions to reinstate the jury's finding of anticipation.  The Federal Circuit explained that under its precedent, an old product is not patentable even if it is made by a new process, and further clarified that this principle applies to method-of-treatment claims that include product-by-process limitations.  The Federal Circuit explained that the claims' requirement that the polypeptide is “recombinant” merely described the process by which the product is formed, and does not add structural limitations.  Under the proper legal framework, the Federal Circuit held that a reasonable jury could find the claims anticipated.

Read the full post here

Originally Published by Winston & Strawn, January 2021

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More